Clinical trial
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
NCT00492050 · M.D. Anderson Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00492050 |
|---|---|
| Title | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia |
| Official title | Primary Treatment of Waldenstrom's Macroglobulinemia With Bortezomib (Velcade) and Rituximab (Rituxan) Followed by Autologous Stem Cell Collection |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Bortezomib, Rituximab, Valacyclovir |
| Enrollment | 46 |
| Start date | Aug 2, 2006 |
| Primary completion | Feb 28, 2021 |
| Completion | Jun 28, 2026 |
| First posted | Jun 27, 2007 |
| Last update posted | Sep 2, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: